Article Sidebar

PDF
Date Published: 17/03/2023
Abstract Views: 407
Views PDF: 168
DOI: https://doi.org/10.51298/vmj.v524i1A.4642
Issue
Vol. 524 No. 1A (2023)
Section
Các bài báo
How to Cite
Trần , K. S. ., Lại , T. T. ., Ngô, H. T. ., Trần, Đặng Đăng K. ., Phạm , T. M. ., Trần , T. B. P. ., Đoàn , T. T. N. ., & Nguyễn, T. K. . (2023). THE STUDY OF PROPORTION AND SOME OF THE FACTORS RELATED TO THE ELEVATION OF BLOOD GALECTIN-3 IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION. Vietnam Medical Journal, 524(1A). https://doi.org/10.51298/vmj.v524i1A.4642

THE STUDY OF PROPORTION AND SOME OF THE FACTORS RELATED TO THE ELEVATION OF BLOOD GALECTIN-3 IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Kim Sơn Trần 1,, Trung Tín Lại 2, Hoàng Toàn Ngô1, Đặng Đăng Khoa Trần1, Thị Minh Phạm 1, Thị Bích Phương Trần 1, Thị Tuyết Ngân Đoàn 1, Trung Kiên Nguyễn1
1 Can Tho University of Medicine - Pharmacy
2 Can Tho city Heart Hospital

Main Article Content

Abstract

Objective: In patients with heart disease and a reduced ejection fraction, a review investigated the proportion and other variables associated with elevated blood galectin-3. Subjects and methods: 122 heart failure patients with reduced ejection fraction have been the subjects of a cross-sectional descriptive study from 2018 to 2019 at Can Tho University of Medicine and Pharmacy Hospital. Results: In research with 122 individuals with heart failure, 14 (11.48%) showed elevated blood galectin-3 (22.1 ng/mL), while the remaining 88.52 percent did not. Elevated galectin-3 is associated with a history of coronary artery disease, NT-proBNP >1800 pg/mL, and a waist circumference > 90 cm in people with heart failure. Elevated blood levels of galactin-3 were linked to increased NT-proBNP and EF levels in a multivariate regression study of heart failure diagnostic time. Conclusion: Blood galectin-3 is frequently increased in heart failure patients with lower ejection fraction and is correlated with NT-proBNP, ejection fraction, and delay in diagnosis of heart failure

Article Details

Keywords

Heart failure and reduced ejection fraction, galectin-3

References

1. AIshii M. (2000), "The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension", Nihon Rinsho, 58 Suppl 1, pp. 267-275.
2. ADA (2017), "Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers", Clin Diabetes. 35 (1), pp. 5-26.
3. Christenson R. H. (2010), "Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure", Clin Biochem. 43 (7-8), pp. 683-690.
4. de Boer R. A. (2012), "The fibrosis marker galectin-3 and outcome in the general population", J Intern Med. 272 (1), pp. 55-64.
5. ESC (2017), "Corrigendum to: '2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure'", Eur Heart J.
6. Ho J. E. (2012), "Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community", J Am Coll Cardiol. 60 (14), pp. 1249-1256.
7. Lok D. J. et al. (2010), "Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study", Clin Res Cardiol. 99 (5), pp. 323-328.
8. Welsh P. (2013), "N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS", Eur Heart J. 34 (6), pp. 443-450.
9. Ho J. E. (2012), "Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community", Journal of the American College of Cardiology. 60 (14), pp. 1249.
10. Shah R. V. (2010), "Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure", European journal of heart failure. 12 (8), pp. 826-832.